SFI Health™ Launches Equazen® Supplements in Portugal for Cognitive Support
SFI Health™ Launches Equazen® Supplements in Portugal for Cognitive Support SFI Health™ EMEA, the regional arm of SFI Health™, a global leader in natural healthcare, is excited to announce the upcoming launch of Equazen® products in Portugal. SFI Health™ is…
Children’s of Alabama Completes 150+ Sedation-Free TNEs Using EvoEndo System
Children’s of Alabama Completes 150+ Sedation-Free TNEs Using EvoEndo System EvoEndo®, Inc. (EvoEndo) is proud to announce that Children’s of Alabama has successfully completed over 150 Sedation-Free Transnasal Endoscopies (TNEs) using the EvoEndo® Single-Use Endoscopy System. This makes Children’s of…
Osivax Secures Funding to Advance Influenza Vaccine Development
Osivax Secures Funding to Advance Influenza Vaccine Development Osivax, a biopharmaceutical company focused on developing vaccines for broad-spectrum protection against rapidly mutating respiratory viruses, has announced the successful first close of its Series B funding round, securing €10 million from…
Actio Biosciences Doses First Participant in Phase 1 Trial of ABS-0871 for CMT2C
Actio Biosciences Doses First Participant in Phase 1 Trial of ABS-0871 for CMT2C Actio Biosciences, a clinical-stage biotechnology company focused on using its “one to many” paradigm in genetics and precision medicine, has announced that the first participant has been…
Talkdesk AI Agents Enhance Healthcare Patient and Member Experience
Talkdesk AI Agents Enhance Healthcare Patient and Member Experience Talkdesk®, Inc., a global leader in artificial intelligence (AI)-powered customer experience (CX) technology, is empowering healthcare organizations to deliver a new level of integrated self-service. Their innovative solution, Talkdesk AI Agents…
SOTIO Reveals Promising Preclinical Data on SOT109 for Colorectal Cancer
SOTIO Reveals Promising Preclinical Data on SOT109 for Colorectal Cancer SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, has unveiled groundbreaking preclinical data for SOT109, a novel antibody-drug conjugate (ADC) designed to target cadherin-17 (CDH17). The data, presented…
Lightbeam Health to Showcase AI Solution Transforming Patient Outcomes at HIMSS 2025
Lightbeam Health to Showcase AI Solution Transforming Patient Outcomes at HIMSS 2025 Lightbeam Health Solutions, a leader in population health technology, will be an exhibiting sponsor at HIMSS25, held from March 3-6, 2025, in Las Vegas, NV. Attendees are invited…
Elucid Appoints Clinical and Commercial Leaders Before PlaqueIQ™ Launch
Elucid Appoints Clinical and Commercial Leaders Before PlaqueIQ™ Launch Elucid, an AI-driven medical technology company specializing in providing physicians with a more accurate view of atherosclerosis for tailored treatment decisions, has strengthened its clinical and commercial teams with several senior…
KalVista Presents Latest Sebetralstat Findings at AAAAI 2025
KalVista Presents Latest Sebetralstat Findings at AAAAI 2025 KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the presentation of new data on sebetralstat at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) Joint Congress…
ATEC Announces Proposed Offering of Convertible Senior Notes
ATEC Announces Proposed Offering of Convertible Senior Notes Alphatec Holdings, Inc. (Nasdaq: ATEC), a company focused on revolutionizing spine surgery, has announced its intention to offer $300,000,000 in aggregate principal amount of convertible senior notes due 2030 (the “notes”) in…
Gensaic Partners with Novo Nordisk to Develop Next-Gen Precision Therapies
Gensaic Partners with Novo Nordisk to Develop Next-Gen Precision Therapies Gensaic, Inc., a biotechnology firm specializing in AI-driven protein design and biological insights to discover ligands for tissue-selective intracellular delivery, has announced a new license and discovery collaboration with global…
Protagonist and Takeda Report Positive Phase 3 VERIFY Study Results of Rusfertide for Polycythemia Vera
Protagonist and Takeda Report Positive Phase 3 VERIFY Study Results of Rusfertide for Polycythemia Vera Protagonist Therapeutics, Inc. and Takeda have announced positive topline results from their Phase 3 VERIFY study of rusfertide, a first-in-class investigational hepcidin mimetic peptide therapeutic,…